newsfilter
← Latest News
GlobeNewswire·

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

  • Caribou Biosciences, Inc. (NASDAQ: CRBU) announced its president & CEO Rachel Haurwitz, PhD will join a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.
  • The webcast is accessible via the Events page on Caribou's website & will remain available for at least 30 days post-event.
  • Caribou utilizes its chRDNA genome-editing technology to develop cell therapies with enhanced precision against devastating diseases.
  • The company's pipeline includes vispacabtagene regedleucel (vispa-cel) & CB-011, which are off-the-shelf CAR-T therapies designed for hematologic malignancies.
  • Investor & media inquiries can be directed to Peggy Vorwald, PhD, via investor.relations@cariboubio.com or media@cariboubio.com.